Literature DB >> 378674

Factors affecting warfarin requirements. A prospective population study.

P A Routledge, P H Chapman, D M Davies, M D Rawlins.   

Abstract

In 228 ambulatory patients receiving treatment with warfarin, there was a progressive decline in the dose required to produce an equivalent degree of anticoagulant control with increasing age from the third decade onwards. However, the relationship between age and dose was significant only in patients receiving warfarin after episodes of venous thromboembolism or because of coronary artery disease. Patient weight was also related to warfarin requirements, although it was less important a determinant than age.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378674     DOI: 10.1007/bf00558434

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants.

Authors:  M A PEYMAN
Journal:  Acta Med Scand Suppl       Date:  1958

2.  Clinical trial of phenylindanedione as an anticoagulant.

Authors:  M TOOHEY
Journal:  Br Med J       Date:  1953-03-21

3.  Age as a determinant of sensitivity to warfarin.

Authors:  A M Shepherd; D S Hewick; T A Moreland; I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

4.  Determinants of anticoagulant control in patients receiving warfarin.

Authors:  K O'Malley; I H Stevenson; C A Ward; A J Wood; J Crooks
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

5.  The influence of age on the response to anticoagulants.

Authors:  S Husted; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

6.  Control of warfarin therapy in the elderly.

Authors:  J T Eccles
Journal:  Age Ageing       Date:  1975-08       Impact factor: 10.668

7.  Problems encountered in long-term treatment with anticoagulants.

Authors:  S Husted; F Andreasen
Journal:  Acta Med Scand       Date:  1976
  7 in total
  24 in total

1.  Spontaneous hyphaema as a result of systemic anticoagulation in previously abnormal eyes.

Authors:  R Holden
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

Review 2.  The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

3.  Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients.

Authors:  Katie B Tellor; Steffany N Nguyen; Amanda C Bultas; Anastasia L Armbruster; Nicholas A Greenwald; Abigail M Yancey
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-06-19

Review 4.  The effects of food on drug bioavailability.

Authors:  P A Winstanley; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

5.  Investigation of patients with abnormal response to warfarin.

Authors:  D P Bentley; G Backhouse; A Hutchings; R L Haddon; B Spragg; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

6.  [Oral anticoagulant therapy: analysis of the efficacy of a dosage guide].

Authors:  F Jobin; M Vigneault
Journal:  CMAJ       Date:  1986-07-15       Impact factor: 8.262

Review 7.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

8.  Pharmacogenetics of anticoagulants.

Authors:  Anders Rane; Jonatan D Lindh
Journal:  Hum Genomics Proteomics       Date:  2010-09-13

Review 9.  Medication prescribing in frail older people.

Authors:  Ruth E Hubbard; M Sinead O'Mahony; Kenneth W Woodhouse
Journal:  Eur J Clin Pharmacol       Date:  2012-09-11       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.